Citation: | HUANG Jia-qi, ZHONG Li, ZHANG Zhi-hui, WU Na, WU Long, XIANG Ying, LI Cheng-ying, LI Ya-fei. Construction and comparative analysis of prognostic scoring system in patients with atrial fibrillation[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(4): 473-479. doi: 10.16462/j.cnki.zhjbkz.2020.04.020 |
Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: areport from the Taiwan nationwide AF cohort study[J]. Chest, 2018, 153(2): 453-466. DOI: 10.1016/j.chest.2017.10.001.
|
European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology(ESC)[J]. Eur Heart J, 2010, 31(19): 2369-2429. DOI: 10.1093/eurheartj/ehq278.
|
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007, 146(12): 857-867. DOI: 10.7326/0003-4819-146-12-200706190-00007.
|
The SPAF III writing committee for the stroke prevention in atrial fibrillation investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: stroke prevention in atrial fibrillation III study[J]. JAMA, 1998, 279(16): 1273-1277. DOI: 10.1001/jama.279.16.1273.
|
Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation[J]. JAMA, 2001, 285(22): 2864-2870. DOI: 10.1001/jama.285.22.2864.
|
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation[J]. Chest, 2010, 137(2): 263-272. DOI: 10.1378/chest.09-1584.
|
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J, 2016, 37(38): 2893-2962. DOI: 10.1093/eurheartj/ehw210.
|
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the heart rhythm society[J]. Circulation, 2014, 130(23): 199-267. DOI: 10.1161/cir.0000000000000041.
|
Apiyasawat S, Tangcharoen T, Wisaratapong T, et al. CHA2DS2-VASc scores predict mortality after hospitalization for atrial fibrillation[J]. Int J Cardiol, 2015, 185: 293-296. DOI: 10.1016/j.ijcard.2015.03.180.
|
Hijazi Z, Lindback J, Alexander JH, et al. The ABC(age, biomarkers, clinical history)stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation[J]. Eur Heart J, 2016, 37(20): 1582-1590. DOI: 10.1093/eurheartj/ehw054.
|
Hijazi Z, Oldgren J, Lindback J, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC(age, biomarkers, clinical history)death risk score[J]. Eur Heart J, 2018, 39(6): 477-485. DOI: 10.1093/eurheartj/ehx584.
|
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization[J]. Clin Cancer Res, 2004, 10(21): 7252-7259. DOI: 10.1158/1078-0432.ccr-04-0713.
|
Kang L, Chen W, Petrick NA, et al. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach[J]. Stat Med, 2015, 34(4): 685-703. DOI: 10.1002/sim.6370.
|
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score(HAS-BLED)to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey[J]. Chest, 2010, 138(5): 1093-1100. DOI: 10.1378/chest.10-0134.
|
Hijazi Z, Oldgren J, Siegbahn A, et al. Application of biomarkers for risk stratification in patients with atrial fibrillation[J]. Clin Chem, 2017, 63(1): 152-164. DOI: 10.1373/clinchem.2016.255182.
|
Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy(RE-LY)substudy[J]. Circulation, 2012, 125(13): 1605-1616. DOI: 10.1161/circulationaha.111.038729.
|
Wallentin L, Hijazi Z, Andersson U, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation(ARISTOTLE)trial[J]. Circulation, 2014, 130(21), 130: 1847-1858. DOI: 10.1161/circulationaha.114.011204.
|
Agency for Healthcare Research and Quality(US). Stroke prevention in patients with atrial fibrillation: a systematic review update[R]. Rockville, MD, 2018.
|
Proietti M, Farcomeni A, Romiti GF, et al. Association between clinical risk scores and mortality in atrial fibrillation: systematic review and network meta-regression of 669, 000 patients[J]. Eur J Prev Cardiol, 2018: 2047487318817662. DOI: 10.1177/2047487318817662.
|
Fanola CL, Giugliano RP, Ruff CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial[J]. Eur Heart J, 2017, 38(12): 888-896. DOI: 10.1093/eurheartj/ehw565.
|
Fox KAA, Lucas JE, Pieper KS, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation[J]. BMJ Open, 2017, 7(12): e017157. DOI: 10.1136/bmjopen-2017-017157.
|
Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye[J]. Lancet Oncol, 2015, 16(4): e173-180. DOI: 10.1016/s1470-2045(14)71116-7.
|